Occudo Quantitative Strategies LP Acquires New Position in Privia Health Group, Inc. (NASDAQ:PRVA)

Occudo Quantitative Strategies LP acquired a new stake in shares of Privia Health Group, Inc. (NASDAQ:PRVA) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 10,567 shares of the company’s stock, valued at approximately $207,000.

A number of other institutional investors have also modified their holdings of the business. Deutsche Bank AG boosted its stake in Privia Health Group by 11.7% during the 4th quarter. Deutsche Bank AG now owns 272,973 shares of the company’s stock valued at $5,337,000 after purchasing an additional 28,556 shares during the period. Durable Capital Partners LP boosted its stake in Privia Health Group by 3.4% during the 4th quarter. Durable Capital Partners LP now owns 11,487,843 shares of the company’s stock valued at $224,587,000 after purchasing an additional 378,255 shares during the period. Bank of America Corp DE boosted its stake in Privia Health Group by 5.1% during the 4th quarter. Bank of America Corp DE now owns 1,021,763 shares of the company’s stock valued at $19,975,000 after purchasing an additional 49,389 shares during the period. BNP Paribas Financial Markets acquired a new position in Privia Health Group during the 4th quarter valued at about $4,321,000. Finally, Algert Global LLC boosted its stake in Privia Health Group by 639.1% during the 4th quarter. Algert Global LLC now owns 108,048 shares of the company’s stock valued at $2,112,000 after purchasing an additional 93,429 shares during the period. Institutional investors own 94.48% of the company’s stock.

Privia Health Group Stock Performance

Privia Health Group stock opened at $25.02 on Friday. The firm has a market cap of $3.05 billion, a PE ratio of 250.23, a P/E/G ratio of 3.47 and a beta of 0.87. The firm’s 50 day moving average price is $23.36 and its two-hundred day moving average price is $22.54. Privia Health Group, Inc. has a twelve month low of $15.92 and a twelve month high of $26.09.

Analysts Set New Price Targets

A number of analysts have recently weighed in on PRVA shares. Truist Financial upped their price target on shares of Privia Health Group from $27.00 to $28.00 and gave the stock a “buy” rating in a research note on Thursday, April 10th. JMP Securities reaffirmed a “market outperform” rating and issued a $29.00 price target on shares of Privia Health Group in a research note on Monday, April 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $30.00 price target on shares of Privia Health Group in a research note on Thursday, April 10th. Canaccord Genuity Group upped their price target on shares of Privia Health Group from $29.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Finally, Barclays increased their target price on shares of Privia Health Group from $21.00 to $23.00 and gave the company an “equal weight” rating in a research note on Thursday, April 10th. One research analyst has rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Privia Health Group has an average rating of “Buy” and a consensus price target of $27.38.

Insider Buying and Selling at Privia Health Group

In other Privia Health Group news, Director Matthew Shawn Morris sold 10,309 shares of the company’s stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total value of $240,508.97. Following the transaction, the director now owns 59,792 shares in the company, valued at approximately $1,394,947.36. This represents a 14.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Parth Mehrotra sold 15,100 shares of the company’s stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $23.33, for a total transaction of $352,283.00. Following the completion of the transaction, the chief executive officer now owns 454,281 shares in the company, valued at approximately $10,598,375.73. This represents a 3.22% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 51,579 shares of company stock worth $1,226,367. 10.70% of the stock is currently owned by company insiders.

Privia Health Group Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.